BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fan Z, Luo G, Gong Y, Xu H, Qian Y, Deng S, Huang Q, Yang C, Cheng H, Jin K, Liu C, Yu X. Prognostic Value of the C-Reactive Protein/Lymphocyte Ratio in Pancreatic Cancer. Ann Surg Oncol 2020;27:4017-25. [PMID: 32144621 DOI: 10.1245/s10434-020-08301-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Badowska-Kozakiewicz A, Fudalej M, Kwaśniewska D, Durlik M, Nasierowska-Guttmejer A, Mormul A, Włoszek E, Czerw A, Banaś T, Deptała A. Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma-Prevalence, Clinicopathological Variables, and Clinical Outcomes. Cancers (Basel) 2022;14:2840. [PMID: 35740504 DOI: 10.3390/cancers14122840] [Reference Citation Analysis]
2 Ko CA, Fang KH, Hsu CM, Lee YC, Chang GH, Huang EI, Tsai MS, Tsai YT. The preoperative C-reactive protein-lymphocyte ratio and the prognosis of oral cavity squamous cell carcinoma. Head Neck 2021;43:2740-54. [PMID: 33991004 DOI: 10.1002/hed.26738] [Reference Citation Analysis]
3 Xu R, Xiao S, Ding Z, Zhao P. The Value of the C-Reactive Protein-to-Lymphocyte Ratio for Predicting Lymphovascular Invasion Based on Nutritional Status in Gastric Cancer. Technol Cancer Res Treat 2022;21:15330338221106517. [PMID: 35695253 DOI: 10.1177/15330338221106517] [Reference Citation Analysis]
4 Ma Y, Su X, Li X, Zhi X, Jiang K, Xia J, Li H, Yan C, Zhou L. Combined detection of peripheral blood VEGF and inflammation biomarkers to evaluate the clinical response and prognostic prediction of non-operative ESCC. Sci Rep 2021;11:15305. [PMID: 34315926 DOI: 10.1038/s41598-021-94329-8] [Reference Citation Analysis]
5 Nissen M, Tröbs RB. Levels of C-Reactive Protein and Sodium May Differentiate a Perforated Appendix from a Nonperforated Appendix in Children. Biomed Res Int 2021;2021:9957829. [PMID: 34222491 DOI: 10.1155/2021/9957829] [Reference Citation Analysis]
6 Tong H, Huang Z, Chen H, Zhou B, Liao Y, Wang Z. Emodin Reverses Gemcitabine Resistance of Pancreatic Cancer Cell Lines Through Inhibition of IKKβ/NF-κB Signaling Pathway. Onco Targets Ther 2020;13:9839-48. [PMID: 33061461 DOI: 10.2147/OTT.S253691] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Matsui Y, Matsuda A, Maejima A, Shinoda Y, Nakamura E, Komiyama M, Fujimoto H. The clinical significance of perioperative inflammatory index as a prognostic factor for patients with retroperitoneal soft tissue sarcoma. Int J Clin Oncol 2022. [PMID: 35319075 DOI: 10.1007/s10147-022-02150-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Giannis D, Moris D, Barbas AS. Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians. Cancers (Basel) 2021;13:1071. [PMID: 33802340 DOI: 10.3390/cancers13051071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Li S, Zhang G, Lu Y, Zhao T, Gao C, Liu W, Piao Y, Chen Y, Huang C, Chang A, Hao J. Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer. Front Oncol 2022;12:841819. [DOI: 10.3389/fonc.2022.841819] [Reference Citation Analysis]
10 Fan Z, Luo G, Gong Y, Liu C, Yu X. ASO Author Reflections: C-Reactive Protein/Lymphocyte Ratio as a Promising Marker for Predicting Survival in Pancreatic Cancer. Ann Surg Oncol 2020;27:4026-7. [PMID: 32270422 DOI: 10.1245/s10434-020-08335-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Feng C, Yu H, Lei H, Cao H, Chen M, Liu S. A prognostic model using the neutrophil-albumin ratio and PG-SGA to predict overall survival in advanced palliative lung cancer. BMC Palliat Care 2022;21:81. [PMID: 35585628 DOI: 10.1186/s12904-022-00972-x] [Reference Citation Analysis]